| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00259-004-1687-6 |
| P698 | PubMed publication ID | 15565331 |
| P2093 | author name string | Harald J Hoekstra | |
| Albert J H Suurmeijer | |||
| Philip H Elsinga | |||
| Pieter L Jager | |||
| David C P Cobben | |||
| Lukas B Been | |||
| P2860 | cites work | Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis | Q24603316 |
| The Ki-67 protein: from the known and the unknown | Q28143714 | ||
| Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine | Q28318354 | ||
| Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides | Q28621379 | ||
| Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis | Q31950730 | ||
| A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer | Q33911572 | ||
| 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. | Q34197349 | ||
| 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. | Q34211088 | ||
| Human thymidine kinase 1. Regulation in normal and malignant cells | Q34296535 | ||
| In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. | Q34363872 | ||
| Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value | Q34631710 | ||
| Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients | Q34747081 | ||
| Effectiveness of positron emission tomography for the detection of melanoma metastases | Q34747452 | ||
| New diagnostic techniques in staging in the surgical treatment of cutaneous malignant melanoma | Q34996844 | ||
| PET scan imaging in oncology | Q35175450 | ||
| In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography | Q35596074 | ||
| Purine and pyrimidine metabolism in human gliomas: relation to chromosomal aberrations | Q36079980 | ||
| High radiochemical yield synthesis of 3'-deoxy-3'-[18F]fluorothymidine using (5'-O-dimethoxytrityl-2'-deoxy-3'-O-nosyl-beta-D-threo pentofuranosyl)thymine and its 3-N-BOC-protected analogue as a labeling precursor | Q38520917 | ||
| Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivity | Q39705491 | ||
| Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. | Q40582151 | ||
| Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. | Q40609681 | ||
| In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker. | Q41024294 | ||
| Thymidine concentrations in serum and urine of different animal species and man | Q41346695 | ||
| Proliferation in non-Hodgkin's lymphomas as determined by immunohistochemical double staining for Ki-67 | Q41853951 | ||
| Enhanced in vitro inhibition of HIV-1 replication by 3'-fluoro-3'-deoxythymidine compared to several other nucleoside analogs | Q42211069 | ||
| Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs | Q43458802 | ||
| FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. | Q43991956 | ||
| 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. | Q44030329 | ||
| Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs | Q44098300 | ||
| Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[(18)F]fluoro-3'-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines. | Q44112084 | ||
| Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. | Q44128080 | ||
| Early changes in [18F]FLT uptake after chemotherapy: an experimental study | Q44192327 | ||
| In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumor | Q44214948 | ||
| Potential impact of [ 18 F]3'-deoxy-3'-fluorothymidine versus [ 18 F]fluoro-2-deoxy-d-glucose in positron emission tomography for colorectal cancer | Q44435453 | ||
| Synthesis of 2'-deoxy-2'-[18F]fluoro-beta-D-arabinofuranosyl nucleosides, [18F]FAU, [18F]FMAU, [18F]FBAU and [18F]FIAU, as potential PET agents for imaging cellular proliferation. Synthesis of [18F]labelled FAU, FMAU, FBAU, FIAU. | Q44439632 | ||
| [18F]FLT PET for diagnosis and staging of thoracic tumours | Q44536500 | ||
| Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. | Q44576349 | ||
| PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls | Q44576352 | ||
| The role of FDG-PET scan in staging patients with nonsmall cell carcinoma | Q44577935 | ||
| Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. | Q44597631 | ||
| 3'-18F-fluoro-3'-deoxy-L-thymidine: a new tracer for staging metastatic melanoma? | Q44683651 | ||
| 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET. | Q44762727 | ||
| PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study | Q44780804 | ||
| Detection and grading of soft tissue sarcomas of the extremities with (18)F-3'-fluoro-3'-deoxy-L-thymidine. | Q44795401 | ||
| Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. | Q44836743 | ||
| Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer? | Q45096181 | ||
| Enhanced expression of thymidine kinase in human cells following ionizing radiation. | Q45870843 | ||
| Synthesis of 2'-fluoro-5-[11C]-methyl-1-beta-D-arabinofuranosyluracil ([11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. | Q46701257 | ||
| Brain tumor imaging with PET and 2-[carbon-11]thymidine | Q48108797 | ||
| 2-[C-11]thymidine imaging of malignant brain tumors. | Q48286386 | ||
| Relationship between plasma concentrations of 3'-deoxy-3'-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. | Q54019588 | ||
| Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. | Q54117465 | ||
| Sentinel lymph node biopsy as an indicator for axillary dissection in early breast cancer | Q57194333 | ||
| Flow cytometric analysis by bromodeoxyuridine/DNA assay of cell cycle perturbation of methotrexate-treated mouse L1210 leukemia cells | Q68433208 | ||
| Structural modifications at the 2'- and 3'-positions of some pyrimidine nucleosides as determinants of their interaction with the mouse erythrocyte nucleoside transporter | Q70667382 | ||
| FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma | Q71197645 | ||
| In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck | Q72430101 | ||
| Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer | Q73183299 | ||
| Sentinel lymphadenectomy in breast cancer | Q73443112 | ||
| FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models | Q73537175 | ||
| Radiosynthesis of 3'-deoxy-3'-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo | Q73694089 | ||
| L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer | Q74455936 | ||
| Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma | Q74545949 | ||
| Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging | Q77974747 | ||
| P433 | issue | 12 | |
| P1104 | number of pages | 14 | |
| P304 | page(s) | 1659-1672 | |
| P577 | publication date | 2004-12-01 | |
| P1433 | published in | European Journal of Nuclear Medicine and Molecular Imaging | Q15708890 |
| P1476 | title | [18F]FLT-PET in oncology: current status and opportunities | |
| P478 | volume | 31 |
| Q33769525 | (18)F-FLT PET/CT imaging in a Wister rabbit inflammation model |
| Q46548926 | 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma |
| Q37581739 | 18F-FLT and 18F-FDG PET-CT imaging in the evaluation of early therapeutic effects of chemotherapy on Walker 256 tumor-bearing rats |
| Q55461622 | 18F-fluorothymidine-pet imaging of glioblastoma multiforme: effects of radiation therapy on radiotracer uptake and molecular biomarker patterns. |
| Q26991479 | 6-[18F]fluoro-L-DOPA: a well-established neurotracer with expanding application spectrum and strongly improved radiosyntheses |
| Q34267713 | A novel in vitro assay to assess phosphorylation of 3'-[(18)F]fluoro-3'-deoxythymidine |
| Q37686084 | A pilot study of 4'-[methyl-11C]-thiothymidine PET/CT for detection of regional lymph node metastasis in non-small cell lung cancer |
| Q52953650 | A pilot study of the diagnostic and prognostic values of FLT-PET/CT for pancreatic cancer: comparison with FDG-PET/CT. |
| Q36341240 | Advances in positron emission tomographic imaging of lung cancer |
| Q38937295 | Apoptosis imaging studies in various animal models using radio-iodinated peptide. |
| Q89510454 | Approaches to PET Imaging of Glioblastoma |
| Q46463044 | Biological image-guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG? |
| Q38420827 | Bioresponsive probes for molecular imaging: concepts and in vivo applications |
| Q38168168 | CNS metastases in breast cancer: old challenge, new frontiers |
| Q36680859 | Calibration test of PET scanners in a multi-centre clinical trial on breast cancer therapy monitoring using 18F-FLT. |
| Q42905409 | Can Evaluation of Targeted Therapy in Oncology Be Improved by Means of 18F-FLT? |
| Q35266071 | Comparison of 4'-[methyl-(11)C]thiothymidine ((11)C-4DST) and 3'-deoxy-3'-[(18)F]fluorothymidine ((18)F-FLT) PET/CT in human brain glioma imaging |
| Q36704588 | Design of radiolabelled ligands for the imaging and treatment of cancer |
| Q34661633 | Diagnosis and evaluation of gastric cancer by positron emission tomography |
| Q37016981 | Diagnostic Value of 11C-Methionine (MET) and 18F-Fluorothymidine (FLT) Positron Emission Tomography in Recurrent High-Grade Gliomas; Differentiation from Treatment-Induced Tissue Necrosis |
| Q53110150 | Diagnostic performance of ¹⁸F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: comparison with ¹⁸F-fluorodeoxyglucose PET/CT. |
| Q40100231 | Disease control intervals in high-risk neuroblastoma |
| Q91859360 | Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes |
| Q33924541 | Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas |
| Q64229701 | Efficacy of 4'-[methyl-11C] thiothymidine PET/CT before and after neoadjuvant therapy for predicting therapeutic responses in patients with esophageal cancer: a pilot study |
| Q35957293 | Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET. |
| Q33889809 | FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study |
| Q37227814 | FLT-PET imaging of radiation responses in murine tumors |
| Q52982567 | FLT-PET/CT diagnosis of primary and metastatic nodal lesions of gastric cancer: comparison with FDG-PET/CT. |
| Q36483845 | Fluorine-18-Labeled Thymidine Positron Emission Tomography (FLT-PET) as an Index of Cell Proliferation after Pharmacological Ascorbate-Based Therapy |
| Q36454757 | Generalized whole-body Patlak parametric imaging for enhanced quantification in clinical PET |
| Q35108246 | Highlighting the Versatility of the Tracerlab Synthesis Modules. Part 1: Fully Automated Production of [F]Labelled Radiopharmaceuticals using a Tracerlab FX(FN). |
| Q89483641 | How Long of a Dynamic 3'-Deoxy-3'-[18F]fluorothymidine ([18F]FLT) PET Acquisition Is Needed for Robust Kinetic Analysis in Breast Cancer? |
| Q35081130 | Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PET |
| Q26798266 | Imaging radiation response in tumor and normal tissue |
| Q44785223 | Impact of different standardized uptake value measures on PET-based quantification of treatment response. |
| Q42092531 | Impact of the definition of peak standardized uptake value on quantification of treatment response |
| Q37077354 | In vivo imaging of cellular proliferation in renal cell carcinoma using 18F-fluorothymidine PET |
| Q37837837 | In vivo small animal imaging: current status and future prospects |
| Q52970700 | Influence of volumetric 4'-[methyl-11C]-thiothymidine PET/CT parameters for prediction of the clinical outcome of head and neck cancer patients. |
| Q64054390 | Intratumoral F-FLT infusion in metabolic targeted radiotherapy |
| Q83834919 | Is 3'-deoxy-3'-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose? |
| Q35633693 | Measuring proliferation in breast cancer: practicalities and applications |
| Q64921890 | Metabolism of Stem and Progenitor Cells: Proper Methods to Answer Specific Questions. |
| Q34496670 | Molecular imaging in cancer treatment |
| Q41862829 | Molecular imaging of therapy response with (18)F-FLT and (18)F-FDG following cyclophosphamide and mTOR inhibition |
| Q30482989 | Molecular imaging: 18F-FDG PET and a whole lot more. |
| Q36345342 | Molecular imaging: what can be used today. |
| Q53010775 | Monitoring Tumor Response After Histone Deacetylase Inhibitor Treatment Using 3'-Deoxy-3'-[18F]-fluorothymidine PET. |
| Q48039426 | Monitoring Tumor Response after Liposomal Doxorubicin in Combination with Liposomal Vinorelbine Treatment Using 3'-Deoxy-3'-[18F]Fluorothymidine PET. |
| Q34333124 | Monitoring early responses to irradiation with dual-tracer micro-PET in dual-tumor bearing mice |
| Q26778463 | Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies |
| Q43653298 | Monitoring tumor response with radiolabeled nucleoside analogs in a hepatoma-bearing mouse model early after doxisome(®) treatment |
| Q36926449 | Non-[18F]FDG PET in clinical oncology |
| Q57679748 | Non-invasive Early Response Monitoring of Nanoparticle-assisted Photothermal Cancer Therapy Using F-FDG, F-FLT, and F-FET PET/CT Imaging |
| Q38673771 | Novel positron emission tomography tracer distinguishes normal from cancerous cells |
| Q52991000 | Organomediated Enantioselective (18)F Fluorination for PET Applications. |
| Q28074449 | PET Metabolic Biomarkers for Cancer |
| Q36746441 | PET and PET/CT for response evaluation in lymphoma: current practice and developments |
| Q27004457 | PET probes beyond (18)F-FDG |
| Q30794621 | Parametric imaging of ¹⁸F-fluoro-3-deoxy-3-L-fluorothymidine PET data to investigate tumour heterogeneity. |
| Q39428846 | Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model |
| Q38775709 | Preclinical Applications of 3'-Deoxy-3'-[18F]Fluorothymidine in Oncology - A Systematic Review |
| Q36971711 | Promises and challenges of positron emission tomography for assessment of sarcoma in daily clinical practice. |
| Q34083326 | Proof-of-concept study of monitoring cancer drug therapy with cerenkov luminescence imaging |
| Q38506552 | Simple and highly efficient synthesis of 3'-deoxy-3'-[18F]fluorothymidine using nucleophilic fluorination catalyzed by protic solvent |
| Q38778088 | Single-Cell Characterization of 18F-FLT Uptake with Radioluminescence Microscopy. |
| Q34203953 | Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications. |
| Q36213599 | The effects of 5-fluoruracil treatment on 3'-fluoro-3'-deoxythymidine (FLT) transport and metabolism in proliferating and non-proliferating cultures of human tumor cells. |
| Q37011086 | The evolving role of nuclear molecular imaging in cancer. |
| Q46816803 | The role of 18F-FLT in cancer imaging: does it really reflect proliferation? |
| Q57292362 | Tracking Tumor Colonization in Xenograft Mouse Models Using Accelerator Mass Spectrometry |
| Q30949446 | Tumor growth prediction with reaction-diffusion and hyperelastic biomechanical model by physiological data fusion |
| Q36335296 | Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation ((18)F-FDG, (64)Cu-ATSM and (18)F-FLT) in a Dog with Fibrosarcoma: The Importance of Individualized Treatment Planning and Monitoring |
| Q35912078 | Usefulness of FDG, MET and FLT-PET studies for the management of human gliomas |
| Q36533822 | Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma. |
| Q63367523 | Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter s |
| Q37237613 | Visualizing cancer and immune cell function with metabolic positron emission tomography |
| Q39456555 | Whole-body biodistribution of 3'-deoxy-3'-[(18) f]fluorothymidine ((18) FLT) in healthy adult cats |
| Q39627244 | Whole-body direct 4D parametric PET imaging employing nested generalized Patlak expectation-maximization reconstruction. |
| Q96343724 | Why Great Mitotic Inhibitors Make Poor Cancer Drugs |
| Q55286904 | [18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer. |
| Q36528174 | [18F]FLT-PET to predict pharmacodynamic and clinical response to cetuximab therapy in Ménétrier's disease |
| Q35496023 | [18F]fluorothymidine PET imaging in the diagnosis of leptomeningeal involvement with diffuse large B-cell lymphoma |
| Q51009203 | ¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study. |
Search more.